Paper - WANFANG MED ONLINE

You Position: Home > Paper

Arsenic trioxide: an ancient drug revived

( views:253, downloads:12 )

Author:: No author available

Journal Title:: Chinese Medical Journal

Issue:: 19

DOI:: 10.3760/cma.j.issn.0366-6999.2012.19.035

Key Word:: acute promyelocytic leukemia;arsenic trioxide;treatment;mechanism

Abstract： Objective To summarize the clinical applications of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL),as well as non-APL malignancies and to discuss the mechanisms and adverse effects involved in ATO administration.Data sources The data in this article were collected from PubMed and CHKD database with relevant English and Chinese articles published from 1957 to 2011,with key words including acute promyelocytic leukemia,arsenic trioxide,treatment,and mechanism.Study selection Articles including any information about ATO in the treatment of APL were selected.Results APL is a rare subtype of acute myeloid leukemia,with dismal prognosis under treatment with traditional chemotherapy.ATO impressively increases the complete remission rate and prolongs survival of patients with APL,with only mild and transient adverse effects.The advances in the understanding of multiple mechanisms involved in ATO treatment will benefit more cancers in future.Conclusion Deeper understanding of mechanisms involved in ATO treatment may provide rationales for future clinical applications in a number of human malignancies.Chin Med J 2012; 125( 19):3556-3560

Reference

[1]张莹,周晋,李殿俊,等.JNK信号传导通路在砷剂治疗白血病中的作用[J].2004,(4).
[2]ZHOU Jin,Wang Wei,WEI Qing-fang,etc.Effects of arsenic trioxide on voltage-dependent potassium channels and on cell proliferation of human multiple myeloma cells[J].2007,(14).
[3]周晋,孟然,杨宝峰.Comparing two arsenic trioxide administration methods in APL therapy[J].2004,(9).
[4]HAN Li-na,ZHOU Jin,Jan Jacob Schuringa,etc.Treatment strategies in acute myeloid leukemia[J].2011,(9).
[5]Zhang Y,Zhou J,Li.Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.[J].2010,115(9).
[6]L K, HILLESTAD.Acute promyelocytic leukemia.[J].1957,159(3).
[7]VanDerReijden,B.A.,Luesink,M.,Linssen,P.C.M.,etc.Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: Triggering the differentiation syndrome[J].2009,114(27).
[8]Warrell, Raymond P.,de The, Hugues,Wang, Zhen-Yi,etc.Acute Promyelocytic Leukemia.[J].1993,329(3).
[9]Wang ZY,Chen Z.Acute promyelocytic leukemia: from highly fatal to highly curable.[J].2008,111(5).
[10]Vey N,Beran M,Slack J,etc.Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.[J].2003,17(8).
[11]L W, Terstappen,Z, Hollander,H, Meiners,etc.Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells.[J].1990,48.
[12]Ruibao Ren.Mechanisms of Bcr-Abl in the Pathogenesis of Chronic Myelogenous Leukaemia[J].2005,5(3).
[13]Gore SD,Emadi A.Arsenic trioxide - An old drug rediscovered.[J].2010,24(4).
[14]N A, Thornberry,Y, Lazebnik.Caspases: enemies within.[J].1998,281(5381).
[15]Thiele J,Arber DA,Vardiman JW.The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.[J].2009,114(5).
[16]Soignet, Steven L.,Maslak, Peter,Wang, Zhu-Gang,etc.Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide.[J].1998,339(19).
[17]Waxman S,Anderson KC.History of the development of arsenic derivatives in cancer therapy.[J].2001,6(Suppl.2).
[18]M E, Huang,Y C, Ye,S R, Chen,etc.Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.[J].1988,72.
[19]Vey N,Bosly A,Guerci A,etc.Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.[J].2006,24(16).
[20].PML targeting eradicates quiescent leukaemia-initiating cells[J].2008,453(TN.7198).
[21]G Q, Chen,X G, Shi,W, Tang,etc.Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.[J].1997,89.
[22]Xiao-Wei,Zhang.Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.[J].2010,328.
[23]JanetD. Rowley,HarveyM. Golomb,Charlotte Dougherty.15/17 Translocation, a Consistent Chromosomal Change in Acute Promyelocytic Leukaemia[J].1977,309(8010).
[24]Jie CF,Jones RJ,Kenedy AA,etc.Role of NADPH oxidase in arsenic-induced reactive. oxygen species formation and cytotoxicity in myeloid leukemia cells[J].2004,101(13).
[25]Tallman MS,Willman CL,Gregory J,etc.Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.[J].2010,116(19).
[26]D. Gary Gilliland,Brian J. P. Huntly.Leukaemia stem cells and the evolution of cancer-stem-cell research[J].2005,5(4).
[27]Gore SD,Gojo I,Sekeres M.Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.[J].2010,28(6).
[28]Seshire A,Bug G,Beissert T,etc.Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.[J].2007,92(3).
[29]Zhu, YM,Zhao, WL,Tang, W,etc.Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia[J].2009,106(9).
[30]Garcia Manero G.Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.[J].2011,86(6).
[31]Nasr R,Guillemin MC,Ferhi O,etc.Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.[J].2008,14(12).
[32]Mao JH,Chen SJ,Zhang XW,etc.From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia.[J].2011,117(24).
[33]Woo SH,Kwak HJ,Park MJ,etc.Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.[J].2005,95(5).
[34]Palumbo A,Anderson K.Multiple myeloma.[J].2011,364(11).
[35]Rizzieri D,Mason J,Saleh M,etc.Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.[J].2006,24(16).
[36]de The H,Chen Z.Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.[J].2010,10(11).
[37]Shi JY,Zheng PZ,Yan H,etc.All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.[J].2004,101(15).
[38]Beksac M,Wu KL,Amadori S,etc.Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.[J].2006,91(12).
[39]Jabbour E,Kantarjian H,Fava C.Advances in the biology and therapy of patients with chronic myeloid leukaemia.[J].2009,22(3).
[40]O'Dwyer M.Multifaceted approach to the treatment of bcr-abl-positive leukemias.[J].2002,7(Suppl.1).